PERIPHERAL T CELL LYMPHOMA

This phase 2 trial tests whether adding the antibody lacutamab to standard chemotherapy (gemcitabine and oxaliplatin) helps people with relapsed or refractory peripheral T-cell lymphoma. About 49 adults whose tumors have a specific marker (KIR3DL2) will receive either the combina…

This early-stage study tested a combination of two drugs (pembrolizumab and pralatrexate) in 13 people with peripheral T-cell lymphoma that had returned or not responded to prior treatment. The goal was to find the safest dose and see if the combo could shrink tumors. The approac…

This early-phase trial tests a new type of immune cell therapy called WU-CART-007 for people with certain blood cancers, including acute myeloid leukemia and T-cell lymphoma, that have come back or not responded to treatment. The therapy uses donor cells that are genetically modi…

This study was designed to test whether adding the drug tazemetostat to standard CHOP chemotherapy could improve outcomes for people with certain types of T-cell lymphoma. The trial was withdrawn before enrolling any participants, so no results are available. It would have includ…

This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers like lung cancer, melanoma, and lymphoma. The main goal is to see if the drug is safe and tolerable, both alone and combined with other treatments. Researchers also chec…

This study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…

This phase 3 trial compares four different chemotherapy combinations to see which works best as a first treatment for peripheral T-cell lymphoma. About 114 newly diagnosed patients will receive one of the regimens, and researchers will measure how many achieve complete remission …

This study looks at whether a new blood test can find tiny bits of tumor DNA in people with T-cell lymphoma. The goal is to see if this test can help doctors track how well treatment is working and watch for signs of the cancer coming back. About 50 adults with newly diagnosed or…

This study looks at whether analyzing tumor DNA from blood samples (called ctDNA) can be a reliable way to monitor peripheral T-cell lymphoma, a rare blood cancer. Researchers will take blood from 45 patients at diagnosis, during treatment, and at relapse to see if the method wor…